Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

<p>– NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies – This is the second NIH-funding received to advance the development of ALG-097558    – First in human Phase 1 study evaluating single/multiple doses of ALG-097558 in healthy volunteers is ongoing – Aligos plans to continue to […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/aligos-therapeutics-announces-award-of-an-8-5-million-niaid-contract-to-advance-development-of-best-in-class-pan-coronavirus-protease-inhibitor-alg-097558/">Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>